trending Market Intelligence /marketintelligence/en/news-insights/trending/ypn9f6dbnvtnx_oivvbhxw2 content esgSubNav
In This List

Shire, Shionogi seek Japanese approval for ADHD drug Intuniv in adults

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Shire, Shionogi seek Japanese approval for ADHD drug Intuniv in adults

Shire plc and Shionogi & Co. Ltd. are seeking Japanese approval for their attention deficit hyperactivity disorder drug Intuniv.

Shionogi submitted a new drug application to expand the indication to include adults with ADHD. The drug, an extended release formulation of guanfacine hydrochloride, is already approved to treat 6 to 17 year-old ADHD patients.

The application is backed by data from a phase 3 study in which Intuniv outperformed placebo at improving global functioning in adults with ADHD.

Dublin's Shire and Japan-based Shionogi are co-developing and commercializing Intuniv under a 2011 licensing contract.

Intuniv is already approved in 36 countries to treat ADHD in children and adolescents. Shire said Japan is the world's third largest ADHD market.